Evidence map›Paper›PMID 38659904›Full record

ArticlebioRxiv : the preprint server for biology2024

Vimentin regulates mitochondrial ROS production and inflammatory responses of neutrophils.

Thao Ngoc Huynh, Jody Toperzer, Allison Scherer, Anne Gumina, Tonya Brunetti, Michael K Mansour, David M Markovitz, Brian C Russo

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Thao Ngoc Huynh
Jody Toperzer
Allison Scherer
Anne Gumina
Tonya Brunetti
Michael K MansourORCID 0000-0001-8892-8695
David M Markovitz
University of Colorado Anschutz Medical Campus · USHarvard University · USUniversity of Michigan · US

Funding

The Role of Intermediate Filaments in InflammationR35GM146923 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Brian Russo · 2022 to 2026
$2.2M
The role of spleen tyrosine kinase (syk) in neutrophil responses to pathogenic fungi.R01AI132638 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MANSOUR, MICHAEL K · 2018 to 2021
$1.6M
The Type 3 Secretion System Translocon Pore in Bacterial PathogenesisK22AI137296 · NIAID · UNIVERSITY OF COLORADO DENVER · PI RUSSO, BRIAN · 2020 to 2021
$268k
NIAID NIH HHS K22 AI137296NIAID NIH HHS R01 AI132638NIGMS NIH HHS R35 GM146923
6 · The paper itself

Abstract

The intermediate filament vimentin is present in immune cells and is implicated in proinflammatory immune responses. Whether and how it supports antimicrobial activities of neutrophils is not well established. Here, we developed an immortalized neutrophil model to examine the requirement of vimentin. We demonstrate that vimentin restricts the production of proinflammatory cytokines and reactive oxygen species (ROS), but enhances phagocytosis and swarming. We observe that vimentin is dispensable for neutrophil extracellular trap (NET) formation, degranulation, and inflammasome activation. Moreover, gene expression analysis demonstrated that the presence of vimentin was associated with changes in expression of multiple genes required for mitochondrial function and ROS overproduction. Treatment of wild-type cells with rotenone, an inhibitor for complex I of the electron transport chain, increases the ROS levels. Likewise, treatment with mitoTEMPO, a SOD mimetic, rescues the ROS production in cells lacking vimentin. Together, these data show vimentin regulates neutrophil antimicrobial functions and alters ROS levels through regulation of mitochondrial activity.

Identifiers

PMID38659904
PMCPMC11042233
OpenAlexW4394813931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.